{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T03:01:22Z","timestamp":1790910082406,"version":"4.1.0"},"reference-count":40,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,12]],"date-time":"2025-03-12T00:00:00Z","timestamp":1741737600000},"content-version":"vor","delay-in-days":376,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Immunity"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1016\/j.immuni.2024.02.008","type":"journal-article","created":{"date-parts":[[2024,3,12]],"date-time":"2024-03-12T12:02:17Z","timestamp":1710244937000},"page":"559-573.e6","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":31,"title":["Epstein-Barr virus gp42 antibodies reveal sites of vulnerability for receptor binding and fusion to B cells"],"prefix":"10.1016","volume":"57","author":[{"given":"Wei","family":"Bu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashish","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathan L.","family":"Board","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"JungHyun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kennichi","family":"Dowdell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yona","family":"Lei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Hostal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tammy","family":"Krogmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanmei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefania","family":"Pittaluga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Marcotrigiano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0238-7176","authenticated-orcid":false,"given":"Jeffrey I.","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.immuni.2024.02.008_bib1","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3002878","article-title":"Epstein-Barr virus: an important vaccine target for cancer prevention","volume":"3","author":"Cohen","year":"2011","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.immuni.2024.02.008_bib2","doi-asserted-by":"crossref","first-page":"3652","DOI":"10.1016\/j.cell.2022.08.026","article-title":"Epstein-Barr virus: Biology and clinical disease","volume":"185","author":"Damania","year":"2022","journal-title":"Cell"},{"key":"10.1016\/j.immuni.2024.02.008_bib3","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1126\/science.abj8222","article-title":"Longitudinal analysis reveals high prevalence of Epstein-Barr virus associated with multiple sclerosis","volume":"375","author":"Bjornevik","year":"2022","journal-title":"Science"},{"key":"10.1016\/j.immuni.2024.02.008_bib4","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1128\/JVI.79.2.841-852.2005","article-title":"Epstein-Barr virus gp42 is posttranslationally modified to produce soluble gp42 that mediates HLA class II immune evasion","volume":"79","author":"Ressing","year":"2005","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.immuni.2024.02.008_bib5","doi-asserted-by":"crossref","first-page":"3987","DOI":"10.1128\/jvi.69.7.3987-3994.1995","article-title":"The Epstein-Barr virus (EBV) BZLF2 gene product associates with the gH and gL homologs of EBV and carries an epitope critical to infection of B cells but not of epithelial cells","volume":"69","author":"Li","year":"1995","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.immuni.2024.02.008_bib6","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1128\/JVI.72.1.158-163.1998","article-title":"Epstein-Barr virus lacking glycoprotein gp42 can bind to B cells but is not able to infect","volume":"72","author":"Wang","year":"1998","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.immuni.2024.02.008_bib7","doi-asserted-by":"crossref","first-page":"5552","DOI":"10.1128\/JVI.72.7.5552-5558.1998","article-title":"Epstein-Barr virus uses different complexes of glycoproteins gH and gL to infect B lymphocytes and epithelial cells","volume":"72","author":"Wang","year":"1998","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.immuni.2024.02.008_bib8","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms13557","article-title":"Structural basis for Epstein-Barr virus host cell tropism mediated by gp42 and gHgL entry glycoproteins","volume":"7","author":"Sathiyamoorthy","year":"2016","journal-title":"Nat. Commun."},{"key":"10.1016\/j.immuni.2024.02.008_bib9","doi-asserted-by":"crossref","first-page":"9444","DOI":"10.1128\/JVI.00572-06","article-title":"Soluble Epstein-Barr virus glycoproteins gH, gL, and gp42 form a 1:1:1 stable complex that acts like soluble gp42 in B-cell fusion but not in epithelial cell fusion","volume":"80","author":"Kirschner","year":"2006","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.immuni.2024.02.008_bib10","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1038\/nm0602-594","article-title":"Alternate replication in B cells and epithelial cells switches tropism of Epstein-Barr virus","volume":"8","author":"Borza","year":"2002","journal-title":"Nat. Med."},{"key":"10.1016\/j.immuni.2024.02.008_bib11","doi-asserted-by":"crossref","first-page":"5557","DOI":"10.1128\/jvi.70.8.5557-5563.1996","article-title":"The extracellular domain of the Epstein-Barr virus BZLF2 protein binds the HLA-DR \u03b2 chain and inhibits antigen presentation","volume":"70","author":"Spriggs","year":"1996","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.immuni.2024.02.008_bib12","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S1097-2765(02)00465-3","article-title":"Structure of the Epstein-Barr virus gp42 protein bound to the MHC class II receptor HLA-DR1","volume":"9","author":"Mullen","year":"2002","journal-title":"Mol. Cell"},{"key":"10.1016\/j.immuni.2024.02.008_bib13","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.str.2008.12.010","article-title":"Structure of Epstein-Barr Virus Glycoprotein 42 Suggests a Mechanism for Triggering Receptor-Activated Virus Entry","volume":"17","author":"Kirschner","year":"2009","journal-title":"Structure"},{"key":"10.1016\/j.immuni.2024.02.008_bib14","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1004309","article-title":"Assembly and Architecture of the EBV B Cell Entry Triggering Complex","volume":"10","author":"Sathiyamoorthy","year":"2014","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.immuni.2024.02.008_bib15","doi-asserted-by":"crossref","first-page":"5946","DOI":"10.1128\/JVI.78.11.5946-5956.2004","article-title":"Mutational analyses of Epstein-Barr virus glycoprotein 42 reveal functional domains not involved in receptor binding but required for membrane fusion","volume":"78","author":"Silva","year":"2004","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.immuni.2024.02.008_bib16","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1016\/j.immuni.2022.10.003","article-title":"Epstein-Barr virus gH\/gL has multiple sites of vulnerability for virus neutralization and fusion inhibition","volume":"55","author":"Chen","year":"2022","journal-title":"Immunity"},{"key":"10.1016\/j.immuni.2024.02.008_bib17","doi-asserted-by":"crossref","first-page":"E8703","DOI":"10.1073\/pnas.1704661114","article-title":"Inhibition of EBV-mediated membrane fusion by anti-gHgL antibodies","volume":"114","author":"Sathiyamoorthy","year":"2017","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.immuni.2024.02.008_bib18","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1016\/j.immuni.2018.03.026","article-title":"An Antibody Targeting the Fusion Machinery Neutralizes Dual-Tropic Infection and Defines a Site of Vulnerability on Epstein-Barr Virus","volume":"48","author":"Snijder","year":"2018","journal-title":"Immunity"},{"key":"10.1016\/j.immuni.2024.02.008_bib19","article-title":"Protective anti-gB neutralizing antibodies targeting two vulnerable sites for EBV-cell membrane fusion","volume":"119","author":"Zhang","year":"2022","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.immuni.2024.02.008_bib20","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-021-26912-6","article-title":"A potent and protective human neutralizing antibody targeting a novel vulnerable site of Epstein-Barr virus","volume":"12","author":"Zhu","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.immuni.2024.02.008_bib21","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1016\/j.immuni.2019.03.010","article-title":"Immunization with Components of the Viral Fusion Apparatus Elicits Antibodies That Neutralize Epstein-Barr Virus in B Cells and Epithelial Cells","volume":"50","author":"Bu","year":"2019","journal-title":"Immunity"},{"key":"10.1016\/j.immuni.2024.02.008_bib22","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1128\/jvi.41.1.258-264.1982","article-title":"Production and characterization of monoclonal antibodies against the Epstein-Barr virus membrane antigen","volume":"41","author":"Strnad","year":"1982","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.immuni.2024.02.008_bib23","doi-asserted-by":"crossref","first-page":"17474","DOI":"10.1073\/pnas.0404535101","article-title":"Cell-surface expression of a mutated Epstein-Barr virus glycoprotein B allows fusion independent of other viral proteins","volume":"101","author":"McShane","year":"2004","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.immuni.2024.02.008_bib24","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1086\/505912","article-title":"A mouse monoclonal antibody against Epstein-Barr virus envelope glycoprotein 350 prevents infection both in\u00a0vitro and in\u00a0vivo","volume":"194","author":"Haque","year":"2006","journal-title":"J.\u00a0Infect. Dis."},{"key":"10.1016\/j.immuni.2024.02.008_bib25","article-title":"Neutralizing Antibodies Protect against Oral Transmission of Lymphocryptovirus","volume":"1","author":"Singh","year":"2020","journal-title":"Cell Rep. Med."},{"key":"10.1016\/j.immuni.2024.02.008_bib26","first-page":"241","article-title":"Primary Immunodeficiencies Associated with EBV Disease","volume":"390","author":"Cohen","year":"2015","journal-title":"Curr. Top. Microbiol. Immunol."},{"key":"10.1016\/j.immuni.2024.02.008_bib27","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.jaci.2022.10.022","article-title":"The diagnosis of severe combined immunodeficiency (SCID): The Primary Immune Deficiency Treatment Consortium (PIDTC) 2022 Definitions","volume":"151","author":"Dvorak","year":"2023","journal-title":"J.\u00a0Allergy Clin. Immunol."},{"key":"10.1016\/j.immuni.2024.02.008_bib28","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1172\/JCI25720","article-title":"Selective generation of functional somatically mutated IgM+CD27+, but not Ig isotype-switched, memory B cells in X-linked lymphoproliferative disease","volume":"116","author":"Ma","year":"2006","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.immuni.2024.02.008_bib29","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1097\/QCO.0000000000000787","article-title":"Epstein-Barr virus posttransplant lymphoproliferative disorder: update on management and outcomes","volume":"34","author":"Lindsay","year":"2021","journal-title":"Curr. Opin. Infect. Dis."},{"key":"10.1016\/j.immuni.2024.02.008_bib30","doi-asserted-by":"crossref","first-page":"8245","DOI":"10.1073\/pnas.95.14.8245","article-title":"Propagation and recovery of intact, infectious Epstein-Barr virus from prokaryotic to human cells","volume":"95","author":"Delecluse","year":"1998","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.immuni.2024.02.008_bib31","doi-asserted-by":"crossref","first-page":"12408","DOI":"10.1128\/JVI.79.19.12408-12415.2005","article-title":"The amino terminus of Epstein-Barr virus glycoprotein gH is important for fusion with epithelial and B cells","volume":"79","author":"Omerovi\u0107","year":"2005","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.immuni.2024.02.008_bib32","doi-asserted-by":"crossref","first-page":"e00510","DOI":"10.1128\/CVI.00510-16","article-title":"Plasmablast response to primary rhesus cytomegalovirus (CMV) infection in a monkey model of congenital CMV transmission","volume":"24","author":"Fan","year":"2017","journal-title":"Clin. Vaccine Immunol."},{"key":"10.1016\/j.immuni.2024.02.008_bib33","doi-asserted-by":"crossref","first-page":"2175","DOI":"10.1016\/j.celrep.2017.02.003","article-title":"Vaccine Elicitation of High Mannose-Dependent Neutralizing Antibodies against the V3-Glycan Broadly Neutralizing Epitope in Nonhuman Primates","volume":"18","author":"Saunders","year":"2017","journal-title":"Cell Rep."},{"key":"10.1016\/j.immuni.2024.02.008_bib34","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-019-10899-2","article-title":"Difficult-to-neutralize global HIV-1 isolates are neutralized by antibodies targeting open envelope conformations","volume":"10","author":"Han","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.immuni.2024.02.008_bib35","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1016\/j.immuni.2014.11.014","article-title":"Antibody light-chain-restricted recognition of the site of immune pressure in the RV144 HIV-1 vaccine trial is phylogenetically conserved","volume":"41","author":"Wiehe","year":"2014","journal-title":"Immunity"},{"key":"10.1016\/j.immuni.2024.02.008_bib36","series-title":"Antibody Engineering","article-title":"Cloning Hybridoma cDNA by RACE","author":"Bradbury","year":"2001"},{"key":"10.1016\/j.immuni.2024.02.008_bib37","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1038\/nature13117","article-title":"Structure of the core ectodomain of the hepatitis C virus envelope glycoprotein 2","volume":"509","author":"Khan","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.immuni.2024.02.008_bib38","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1107\/S2059798319011471","article-title":"Macromolecular structure determination using X-rays, neutrons and electrons: recent developments in Phenix","volume":"75","author":"Liebschner","year":"2019","journal-title":"Acta Crystallogr. D Struct. Biol."},{"key":"10.1016\/j.immuni.2024.02.008_bib39","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1002\/pro.3330","article-title":"MolProbity: More and better reference data for improved all-atom structure validation","volume":"27","author":"Williams","year":"2018","journal-title":"Protein Sci."},{"key":"10.1016\/j.immuni.2024.02.008_bib40","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.virol.2021.06.006","article-title":"Epstein-Barr virus (EBV) hyperimmune globulin isolated from donors with high gp350 antibody titers protect humanized mice from challenge with EBV","volume":"561","author":"Kim","year":"2021","journal-title":"Virology"}],"container-title":["Immunity"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1074761324000840?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1074761324000840?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T08:24:42Z","timestamp":1761035082000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1074761324000840"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":40,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["S1074761324000840"],"URL":"https:\/\/doi.org\/10.1016\/j.immuni.2024.02.008","relation":{},"ISSN":["1074-7613"],"issn-type":[{"value":"1074-7613","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Epstein-Barr virus gp42 antibodies reveal sites of vulnerability for receptor binding and fusion to B cells","name":"articletitle","label":"Article Title"},{"value":"Immunity","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.immuni.2024.02.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}